Search

Displaying results 3461 - 3470 of 10000 in total
  1. Drug

    Ty800

    go.drugbank.com/drugs/DB04989
    Investigational

    The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of <i>S. typhi</i>. It is being developed by AVANT Immunotherapeutics, Inc. … Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against <i>Salmonella typhi</i>, the cause of typhoid fever.

  2. Drug

    Adavosertib

    go.drugbank.com/drugs/DB11740
    Investigational

    MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

  3. Drug

    MK-0533

    go.drugbank.com/drugs/DB15242
    Investigational

    MK-0533 is under investigation in clinical trial NCT00543959 (Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)).

  4. Drug

    Sinapic acid

    go.drugbank.com/drugs/DB08587
    Experimental

    Sinapic acid is a matrix for matrix-assisted laser desorption technique for protein MW determination. It is also a constituent of propolis.

  5. Drug

    Malic acid

    go.drugbank.com/drugs/DB12751
    Investigational

    Malic acid has been used in trials studying the treatment of Xerostomia, Depression, and Hypertension.

    Mixtures: AKE 1100 GLUKOZLU IV SOLOSYONU, 500 ML, AKE 1100 GLUKOZLU IV SOLOSYONU, 1000 ML
  6. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    [A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis. … [L51958] Similar to the previously developed [tafamidis], acoramidis is used to stabilize TTR in its tetrameric form, preventing the formation of amyloidogenic monomers and the progression of amyloidosis

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  7. Drug

    Pumactant

    go.drugbank.com/drugs/DB04955
    Experimental

    It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).

  8. Drug

    DL-Methylephedrine

    go.drugbank.com/drugs/DB11278
    Approved

    Methylephedrine is not legally available in the United States, but has been identified in cases of drug abuse [L2836].

    International brands: Methylhoedrin 10%, Methylephedrine 10% Fuso
  9. Target

    Taste receptor type 2 member 16

    go.drugbank.com/bio_entities/BE0009016
    TargetHumans

    Gustducin-coupled receptor implicated in the perception of bitter compounds in the oral cavity and the gastrointestinal tract. Signals through PLCB2 and the calcium-regulated cation channel TRPM5

    Polypeptides: Taste receptor type 2 member 16
  10. Drug

    Tradipitant

    go.drugbank.com/drugs/DB12580
    ApprovedInvestigational

    [A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2C19 SubstratesSynonyms: (2-(1-(3,5-BIS(TRIFLUOROMETHYL)BENZYL)-5-PYRIDIN-4-YL-1H-1,2,3-TRIAZOL-4-YL)PYRIDIN-3-YL)(2-CHLOROPHENYL)METHANONE, METHANONE, (2-(1-((3,5-BIS(TRIFLUOROMETHYL)PHENYL)METHYL)-5-(4-PYRIDINYL)-1H-1,2,3-TRIAZOL-4-YL)-3-PYRIDINYL)(2-CHLOROPHENYL)-